Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $39
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter maintains a 'Hold' rating on Integra Lifesciences (NASDAQ:IART) and lowers the price target from $41 to $39.
October 26, 2023 | 6:15 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Truist Securities has maintained a 'Hold' rating on Integra Lifesciences and lowered the price target from $41 to $39.
The news directly pertains to Integra Lifesciences (IART) as Truist Securities has maintained a 'Hold' rating on the company and lowered the price target. This could potentially influence investor sentiment and trading decisions, but it does not necessarily indicate a change in the company's fundamentals or performance. Therefore, the short-term impact on the stock price is neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100